Who Paid My Doc
Gregorio Cortes-Maisonet
General Practice San Juan, PR Medical Doctor
NPI 1639151616 CMS profile 119220
1826 Ave Fernandez Juncos, San Juan, PR 00909
General payments
$25,953
Research payments
$202,903
Ownership & investment interest
$0
Research they led as principal investigator
$12,743,812
Through program year 2025, Gregorio Cortes-Maisonet of San Juan, PR is reported in the CMS Open Payments database as having received $25,953 across 149 general payments and $202,903 in research payments paid to them. Separately, studies naming them as principal investigator received $12,743,812 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
13 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,495 | 2 | |
| 2024 | General | $2,166 | 35 | |
| 2024 | Research | $40,368 | 41 | |
| 2023 | General | $12,421 | 39 | |
| 2023 | Research | $2,754 | 5 | |
| 2022 | General | $2,477 | 20 | |
| 2022 | Research | $39,466 | 7 | |
| 2021 | General | $415 | 8 | |
| 2021 | Research | $43,505 | 7 | |
| 2020 | General | $2,377 | 15 | |
| 2020 | Research | $27,415 | 8 | |
| 2019 | General | $4,602 | 30 | |
| 2019 | Research | $49,394 | 22 |
Beside peers
- Gregorio Cortes-Maisonet
- General Practice median
- Middle half of General Practice
- National median
In program year 2025, general payments to Gregorio Cortes-Maisonet were reported at $1,495. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.
Show as a table
| Year | Gregorio Cortes-Maisonet | General Practice median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $4,602 | $107 | $37–$285 | $163 |
| 2020 | $2,377 | $75 | $25–$213 | $114 |
| 2021 | $415 | $93 | $30–$272 | $132 |
| 2022 | $2,477 | $103 | $36–$279 | $149 |
| 2023 | $12,421 | $106 | $34–$276 | $160 |
| 2024 | $2,166 | $114 | $39–$290 | $164 |
| 2025 | $1,495 | $106 | $35–$292 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 44 drugsPart D claims
1,178
Drug cost
$89,772
Branded share of claims
16.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 19 | $18,710 | |
| Synjardy Empagliflozin/Metformin Hcl | Brand | 11 | $17,371 | |
| Rybelsus Semaglutide | Brand | 13 | $14,587 | |
| Soliqua 100-33 Insulin Glargine/Lixisenatide | Brand | 12 | $10,724 | |
| Synjardy Xr Empagliflozin/Metformin Hcl | Brand | 13 | $9,261 | |
| Synthroid Levothyroxine Sodium | Brand | 44 | $3,709 | |
| Pentoxifylline | Generic | 30 | $1,501 | |
| Lantus Insulin Glargine,hum.Rec.Anlog | Brand | 14 | $1,322 | |
| Atorvastatin Calcium | Generic | 83 | $1,004 | |
| Levothyroxine Sodium | Generic | 50 | $791 |
The 10 drugs with the highest cost, of 44 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,210 Part D prescribers listed as General Practice; they describe a distribution and say nothing about conduct.
Payments and prescribing
2 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| COSENTYX |
|
$145 | — | — |
| RINVOQ |
|
$125 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
239 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other General Practice in Puerto Rico
Related records
General Practice in Puerto Rico
Practitioners in the same specialty and state, ranked by reported value.
All General Practice
Everyone recorded under this specialty, nationwide.
Doctors in Puerto Rico
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.